340
Participants
Start Date
August 31, 2020
Primary Completion Date
August 31, 2021
Study Completion Date
December 31, 2021
Additional screening using ultra sensitive RDTs
At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm
Dihydroartemisinin-piperaquin
All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home
Reminders
Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
Institut de Recherche en Sciences de la Santé/ Clinical Research Unit of Nanoro, Ouagadougou
European and Developing Countries Clinical Trials Partnership (EDCTP)
OTHER_GOV
Institut de Recherche en Sciences de la Sante, Burkina Faso
OTHER_GOV